Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity: The GEMINI-1 Randomized Clinical Trial.
Listen to this summary
This phase 3, double-blind, placebo-controlled trial asked whether once-weekly subcutaneous ribupatide, a dual GIP/GLP-1 receptor agonist, produces meaningful weight loss in adults with overweight or obesity (without diabetes) in China. Over 48 weeks, participants receiving 2, 4, or 6 mg ribupatide lost 10.7%, 16.4%, and 17.7% of their body weight, respectively, versus 1.4% with placebo, and 69–88% of treated participants achieved at least 5% weight loss compared with 16% on placebo. Gastrointestinal adverse events were the most common side effects (47–63% vs 23% with placebo), but few participants discontinued treatment because of them.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.

More from JAMA
View all →Nov 19, 2026 · JAMA
Plasma eMTBR-tau as a Biomarker for Chronic Traumatic Encephalopathy Tau Tangle Neuropathology.
Nov 19, 2026 · JAMA
Medical Imaging and Pediatric and Adolescent Brain Tumor Risk.
Nov 17, 2026 · JAMA
Toward a Healthier Future Through Obesity Prevention and Care: The JAMA Summit Report on Obesity.
Nov 16, 2026 · JAMA
A Plasma eMTBR-Tau Immunoassay for Detection of Advanced Insoluble Tau Pathology.
Nov 15, 2026 · JAMA
Tirzepatide in Adolescents With Obesity: The SURMOUNT-ADOLESCENTS Randomized Clinical Trial.
Nov 13, 2026 · JAMA
Fluid eMTBR-tau243 as a Biomarker of Mixed 3-Repeat and 4-Repeat Tau Pathology.
More in Thoracic Surgery (Cardiothoracic Vascular Surgery)
View all →Nov 19, 2026 · Lancet (London, England)
Spontaneous coronary artery dissection: implications for women's health, clinical care, and future research.
Nov 19, 2026 · Lancet (London, England)
Reproductive health in women in Britain from 2010 to 2024: findings from repeated, cross-sectional National Surveys of Sexual Attitudes and Lifestyles (Natsal).
Nov 19, 2026 · Lancet (London, England)
Seasonal mass vaccination with R21/Matrix-M against malaria in The Gambia and Burkina Faso: an open-label, cluster-randomised, controlled trial.
Nov 19, 2026 · The New England journal of medicine
Assessing Multiple Treatment Regimens for Tuberculosis.
Nov 18, 2026 · The New England journal of medicine
Acute Respiratory Distress Syndrome.
Nov 17, 2026 · Lancet (London, England)
Natural ligand-based CAR T-cell therapy targeting BCMA and TACI for relapsed or refractory multiple myeloma (TriPRIL): a non-randomised, phase 1, first-in-human trial.
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR


